RE
ALXN

RBC Europe’s Alexion Pharmaceuticals ALXN Stock Holding History

RBC Europe’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-475
Closed -$53.3K – 1129
2020
Q2 		$53.3K Buy
+475
New +$50.4K ﹤0.01% 433
2019
Q3 		– Sell
-60
Closed -$7.86K – 1088
2019
Q2 		$7.86K Hold
60
– – ﹤0.01% 851
2019
Q1 		$8.11K Buy
+60
New +$7.46K ﹤0.01% 857
2018
Q2 		– Sell
-39
Closed -$4.35K – 1190
2018
Q1 		$4.35K Hold
39
– – ﹤0.01% 969
2017
Q4 		$4.66K Hold
39
– – ﹤0.01% 964
2017
Q3 		$5.47K Buy
+39
New +$5.3K ﹤0.01% 938

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $431B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.47T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return